Analysts Issue Forecasts for Stoke Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Stoke Therapeutics in a research note issued to investors on Tuesday, March 26th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.63) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.28) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.63) EPS, Q4 2024 earnings at ($0.63) EPS, FY2024 earnings at ($2.62) EPS, FY2025 earnings at ($3.45) EPS, FY2026 earnings at ($2.59) EPS, FY2027 earnings at ($0.91) EPS and FY2028 earnings at $0.18 EPS.

STOK has been the topic of a number of other reports. Needham & Company LLC upped their target price on Stoke Therapeutics from $14.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. increased their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a report on Tuesday. Wedbush increased their price objective on Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.63.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $13.50 on Thursday. Stoke Therapeutics has a one year low of $3.35 and a one year high of $16.40. The stock has a market capitalization of $625.05 million, a PE ratio of -5.52 and a beta of 0.68. The business’s fifty day moving average price is $6.07 and its 200-day moving average price is $5.02.

Insider Activity at Stoke Therapeutics

In other news, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the sale, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the sale, the chief executive officer now owns 69,350 shares in the company, valued at $423,035. The disclosure for this sale can be found here. Over the last three months, insiders have sold 37,615 shares of company stock worth $212,852. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. Swiss National Bank raised its position in Stoke Therapeutics by 8.2% during the first quarter. Swiss National Bank now owns 30,500 shares of the company’s stock valued at $642,000 after purchasing an additional 2,300 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Stoke Therapeutics by 20.8% in the first quarter. JPMorgan Chase & Co. now owns 19,608 shares of the company’s stock worth $412,000 after buying an additional 3,374 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Stoke Therapeutics by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock worth $1,320,000 after buying an additional 837 shares during the period. MetLife Investment Management LLC raised its holdings in shares of Stoke Therapeutics by 58.5% in the first quarter. MetLife Investment Management LLC now owns 11,621 shares of the company’s stock worth $245,000 after buying an additional 4,289 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Stoke Therapeutics by 7.6% in the first quarter. Rhumbline Advisers now owns 19,345 shares of the company’s stock worth $407,000 after buying an additional 1,362 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.